Novo Signs $2 Billion Deal With United Labs for Obesity Drug

» Novo Signs $2 Billion Deal With United Labs for Obesity Drug

By:
On:
In: Business
With: 0 Comments




Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity drug, the Danish Ozempic maker’s latest move to refill its pipeline of experimental treatments.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *